Aura Biosciences, Inc.
AURANasdaq
$6.99
↑ +1.5%Jul 17 close · end-of-day
Price
1Y↑ +0.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$471.5M
Enterprise Value
$386.7M
P/E
—
P/S
—
P/B
4.4
EV/EBITDA
—
PEG
—
FCF Yield
-19.4%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$112.4M
Free Cash Flow (TTM)
-$91.6M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-104.8%
ROIC
-417.3%
Debt / Equity
—
Net Cash
$84.8M
Return 1Y
-1.8%
Company profile
Aura Biosciences, Inc. develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
- CEO
- Elisabet de los Pinos
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 50
- Headquarters
- Massachusetts
- Website
- aurabiosciences.com
Management & directors
- Kilroy ConorSee Remarks
- Gibney Anthony SSee Remarks
- Holles Natalie C.See Remarks
- Elazzouzi AmySenior Vice President, Finance
- Hopkins Janet JillChief Medical Officer
- Plavsic MarkChief Technology Officer
- De Los Pinos ElisabetSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
AURA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.50↓ -9.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$22.2M | -$35.3M | -$60.3M | -$85.0M | -$96.1M | -$112.8M |
| Net income | -$22.2M | -$35.3M | -$58.8M | -$76.4M | -$86.9M | -$106.2M |
| Diluted EPS | — | -$8.95 | -$1.96 | -$1.93 | -$1.75 | -$1.76 |
| Operating cash flow | -$24.3M | -$32.4M | -$54.6M | -$63.8M | -$79.8M | -$84.7M |
| Free cash flow | -$25.1M | -$34.5M | -$55.7M | -$64.6M | -$81.1M | -$85.2M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$22.8M | -$23.2M | -$27.8M | -$29.0M | -$28.6M | -$27.9M | -$27.2M | -$34.9M |
| Net income | -$20.3M | -$21.0M | -$25.8M | -$27.5M | -$27.0M | -$26.1M | -$25.6M | -$33.7M |
| Diluted EPS | -$0.41 | -$0.42 | -$0.52 | -$0.55 | -$0.47 | -$0.40 | -$0.34 | -$0.50 |
| Operating cash flow | -$16.1M | -$15.3M | -$24.0M | -$23.4M | -$20.8M | -$20.1M | -$20.5M | -$29.9M |
| Free cash flow | -$16.7M | -$15.6M | -$24.3M | -$23.5M | -$20.8M | -$20.2M | -$20.6M | -$30.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
May 27, 2026
May 20, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-07 | Bender Jeremy | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-07-01 | Kilroy Conor· See Remarks | Award | 14,858 | $0.00 | $0.00 | filing |
| 2026-06-16 | Gibney Anthony S· See Remarks | Sale | 12,824 | $6.42 | $82,330.08 | filing |
| 2026-06-11 | Mattessich Antony C. | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | Johnson David Michael | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | Bitetti Teresa Marie | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-06-11 | Srivastava Sapna | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-05-19 | Holles Natalie C.· See Remarks | Award | 600,118 | $0.00 | $0.00 | filing |
| 2026-05-19 | Holles Natalie C.· See Remarks | Award | 553,844 | $0.00 | $0.00 | filing |
| 2026-05-07 | Matrix Capital Management Company, LP | Sale | 6,922,870 | $5.64 | $39.0M | filing |
| 2026-04-16 | Kilroy Conor· See Remarks | Sale | 11,738 | $7.02 | $82,400.76 | filing |
| 2026-03-02 | de los Pinos Elisabet· See Remarks | Award | 166,000 | $0.00 | $0.00 | filing |
| 2026-03-02 | Kilroy Conor· See Remarks | Award | 62,339 | $0.00 | $0.00 | filing |
| 2026-03-02 | Gibney Anthony S· See Remarks | Award | 71,245 | $0.00 | $0.00 | filing |
| 2026-03-02 | Plavsic Mark· Chief Technology Officer | Award | 62,339 | $0.00 | $0.00 | filing |
| 2026-03-02 | Hopkins Janet Jill· Chief Medical Officer | Award | 89,056 | $0.00 | $0.00 | filing |
| 2026-03-02 | Elazzouzi Amy· Senior Vice President, Finance | Award | 44,528 | $0.00 | $0.00 | filing |
| 2026-02-17 | de los Pinos Elisabet· See Remarks | Sale | 47,648 | $5.06 | $241,098.88 | filing |
| 2026-02-17 | Hopkins Janet Jill· Chief Medical Officer | Sale | 20,401 | $5.06 | $103,229.06 | filing |
| 2026-02-17 | Plavsic Mark· Chief Technology Officer | Sale | 15,890 | $5.05 | $80,244.50 | filing |
| 2026-02-17 | Kilroy Conor· See Remarks | Sale | 12,079 | $5.05 | $60,998.95 | filing |
| 2026-02-17 | Elazzouzi Amy· Senior Vice President, Finance | Sale | 8,549 | $5.06 | $43,257.94 | filing |
| 2026-01-20 | de los Pinos Elisabet· See Remarks | Sale | 16,928 | $4.86 | $82,270.08 | filing |
| 2026-01-20 | Elazzouzi Amy· Senior Vice President, Finance | Sale | 1,581 | $4.86 | $7,683.66 | filing |
| 2025-11-17 | Hopkins Janet Jill· Chief Medical Officer | Sale | 17,109 | $5.42 | $92,730.78 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.